Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

TSH, But Not Thyroid-Stimulating Antibodies, Induces Biphasic Regulation of Gene Expression in Human Thyrocytes.

Jang D, Morgan SJ, Klubo-Gwiezdzinska J, Banga JPS, Neumann S, Gershengorn MC.

Thyroid. 2019 Dec 6. doi: 10.1089/thy.2019.0418. [Epub ahead of print]

PMID:
31805824
2.

The Role of Lithium in Management of Endocrine Tumors-A Comprehensive Review.

Thakur S, Tobey A, Klubo-Gwiezdzinska J.

Front Oncol. 2019 Oct 18;9:1092. doi: 10.3389/fonc.2019.01092. eCollection 2019. Review.

3.

Breathing the air of mitochondrial respiration via an important oncotarget - mitochondrial glycerophosphate dehydrogenase (mGPDH).

Thakur S, Klubo-Gwiezdzinska J.

Oncotarget. 2019 Nov 5;10(60):6400-6402. doi: 10.18632/oncotarget.27292. eCollection 2019 Nov 5. No abstract available.

4.

Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by Gs and Gi/o Proteins.

Neumann S, Malik SS, Marcus-Samuels B, Eliseeva E, Jang D, Klubo-Gwiezdzinska J, Krieger CC, Gershengorn MC.

Mol Pharmacol. 2020 Jan;97(1):2-8. doi: 10.1124/mol.119.117382. Epub 2019 Nov 8.

PMID:
31704717
5.

Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III).

Thakur S, Tobey A, Daley B, Auh S, Walter M, Patel D, Nilubol N, Kebebew E, Patel A, Jensen K, Vasko V, Klubo-Gwiezdzinska J.

Front Oncol. 2019 Sep 18;9:905. doi: 10.3389/fonc.2019.00905. eCollection 2019.

6.

Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL.

Oncologist. 2019 Oct 10. pii: theoncologist.2018-0470. doi: 10.1634/theoncologist.2018-0470. [Epub ahead of print]

PMID:
31601731
7.

The role of the antidiabetic drug metformin in the treatment of endocrine tumors.

Thakur S, Daley B, Klubo-Gwiezdzinska J.

J Mol Endocrinol. 2019 Jul 1. pii: JME-19-0083.R1. doi: 10.1530/JME-19-0083. [Epub ahead of print] Review.

PMID:
31307011
8.

Thyroid emergencies.

Ylli D, Klubo-Gwiezdzinska J, Wartofsky L.

Pol Arch Intern Med. 2019 Aug 29;129(7-8):526-534. doi: 10.20452/pamw.14876. Epub 2019 Jun 25. Erratum in: Pol Arch Intern Med. 2019 Sep 30;129(9):653.

9.

Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

Krieger CC, Boutin A, Jang D, Morgan SJ, Banga JP, Kahaly GJ, Klubo-Gwiezdzinska J, Neumann S, Gershengorn MC.

Endocrinology. 2019 Jun 1;160(6):1468-1479. doi: 10.1210/en.2019-00055.

10.

Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.

Klubo-Gwiezdzinska J, Auh S, Gershengorn M, Daley B, Bikas A, Burman K, Wartofsky L, Urken M, Dewey E, Smallridge R, Chindris AM, Kebebew E.

JAMA Netw Open. 2019 Feb 1;2(2):e187754. doi: 10.1001/jamanetworkopen.2018.7754.

11.

Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Boufraqech M, Patel D, Nilubol N, Powers A, King T, Shell J, Lack J, Zhang L, Gara SK, Gunda V, Klubo-Gwiezdzinska J, Kumar S, Fagin J, Knauf J, Parangi S, Venzon D, Quezado M, Kebebew E.

Thyroid. 2019 Jan;29(1):79-92. doi: 10.1089/thy.2018.0424. Epub 2018 Dec 28.

PMID:
30398411
12.

Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

El Lakis M, Giannakou A, Nockel PJ, Wiseman D, Gara SK, Patel D, Sater ZA, Kushchayeva YY, Klubo-Gwiezdzinska J, Nilubol N, Merino MJ, Kebebew E.

Surgery. 2019 Jan;165(1):50-57. doi: 10.1016/j.surg.2018.05.075. Epub 2018 Oct 14.

13.

Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study.

Klubo-Gwiezdzinska J, Lange M, Cochran E, Semple RK, Gewert C, Brown RJ, Gorden P.

Diabetes Care. 2018 Nov;41(11):2353-2360. doi: 10.2337/dc18-0884. Epub 2018 Sep 10.

14.

The Role of Molecular Diagnostics in the Management of Indeterminate Thyroid Nodules.

Klubo-Gwiezdzinska J, Wartofsky L.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3507-3510. doi: 10.1210/jc.2018-01081. No abstract available.

15.

The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.

Luo H, Tobey A, Auh S, Cochran C, Zemskova M, Reynolds J, Lima C, Burman K, Wartofsky L, Skarulis M, Kebebew E, Klubo-Gwiezdzinska J.

Clin Endocrinol (Oxf). 2018 Oct;89(4):481-488. doi: 10.1111/cen.13806. Epub 2018 Aug 13.

16.

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.

Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, Agarwal S, Klubo-Gwiezdzinska J.

Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.

17.

Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.

Jonklaas J, Murthy S, Liu D, Klubo-Gwiezdzinska J, Krishnan J, Burman KD, Boyle L, Carrol N, Felger E, Loh YP.

Future Sci OA. 2017 Sep 22;4(1):FSO249. doi: 10.4155/fsoa-2017-0087. eCollection 2018 Jan.

18.

Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models.

Klubo-Gwiezdzinska J, Costello J Jr, Jensen K, Patel A, Tkavc R, Van Nostrand D, Burman KD, Wartofsky L, Vasko V.

Endocr Connect. 2017 Oct;6(7):469-478. doi: 10.1530/EC-17-0138. Epub 2017 Aug 8.

19.

Results of Screening in Familial Non-Medullary Thyroid Cancer.

Klubo-Gwiezdzinska J, Yang L, Merkel R, Patel D, Nilubol N, Merino MJ, Skarulis M, Sadowski SM, Kebebew E.

Thyroid. 2017 Aug;27(8):1017-1024. doi: 10.1089/thy.2016.0668. Epub 2017 Jul 19.

20.

MicroRNAs in the thyroid.

Boufraqech M, Klubo-Gwiezdzinska J, Kebebew E.

Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):603-619. doi: 10.1016/j.beem.2016.10.001. Epub 2016 Nov 1. Review.

21.

The Rate and Clinical Significance of Incidental Thyroid Uptake as Detected by Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography.

Nockel P, Millo C, Keutgen X, Klubo-Gwiezdzinska J, Shell J, Patel D, Nilubol N, Herscovitch P, Sadowski SM, Kebebew E.

Thyroid. 2016 Jun;26(6):831-5. doi: 10.1089/thy.2016.0174. Epub 2016 May 6.

22.

Glucose-deprivation increases thyroid cancer cells sensitivity to metformin.

Bikas A, Jensen K, Patel A, Costello J Jr, McDaniel D, Klubo-Gwiezdzinska J, Larin O, Hoperia V, Burman KD, Boyle L, Wartofsky L, Vasko V.

Endocr Relat Cancer. 2015 Dec;22(6):919-32. doi: 10.1530/ERC-15-0402. Epub 2015 Sep 11.

PMID:
26362676
23.

The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.

Kushchayeva Y, Jensen K, Recupero A, Costello J, Patel A, Klubo-Gwiezdzinska J, Boyle L, Burman K, Vasko V.

J Clin Endocrinol Metab. 2014 May;99(5):E734-45. doi: 10.1210/jc.2013-3369. Epub 2014 Jan 31.

PMID:
24483157
24.

Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer.

Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, Burman KD, Wartofsky L, Vasko V.

J Clin Endocrinol Metab. 2013 Aug;98(8):3269-79. doi: 10.1210/jc.2012-3799. Epub 2013 May 24.

PMID:
23709654
25.

Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L.

Endocr Pract. 2013 Jan-Feb;19(1):139-48. doi: 10.4158/EP12244.RA. Review.

26.

The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress.

Klubo-Gwiezdzinska J, Jensen K, Bauer A, Patel A, Costello J Jr, Burman KD, Wartofsky L, Hardwick MJ, Vasko VV.

J Endocrinol. 2012 Aug;214(2):207-16. doi: 10.1530/JOE-12-0081. Epub 2012 May 29.

27.

Thyroid emergencies.

Klubo-Gwiezdzinska J, Wartofsky L.

Med Clin North Am. 2012 Mar;96(2):385-403. doi: 10.1016/j.mcna.2012.01.015. Epub 2012 Feb 17. Review.

PMID:
22443982
28.

Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.

Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L, Vasko V.

Endocr Relat Cancer. 2012 May 24;19(3):447-56. doi: 10.1530/ERC-12-0046. Print 2012 Jun.

PMID:
22389381
29.

Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.

Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L.

Thyroid. 2012 Mar;22(3):310-7. doi: 10.1089/thy.2011.0235. Epub 2012 Feb 7.

30.

BRAF(V600E) mutation analysis from May-Grünwald Giemsa-stained cytological samples as an adjunct in identification of high-risk papillary thyroid carcinoma.

Patel A, Klubo-Gwiezdzinska J, Hoperia V, Larin A, Jensen K, Bauer A, Vasko V.

Endocr Pathol. 2011 Dec;22(4):195-9. doi: 10.1007/s12022-011-9180-9.

PMID:
21948220
31.

Levothyroxine treatment in pregnancy: indications, efficacy, and therapeutic regimen.

Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L.

J Thyroid Res. 2011;2011:843591. doi: 10.4061/2011/843591. Epub 2011 Aug 25.

32.

Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer.

Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, Wartofsky L.

J Clin Endocrinol Metab. 2011 Oct;96(10):3217-25. doi: 10.1210/jc.2011-0494. Epub 2011 Aug 17.

PMID:
21849530
33.

Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis.

Jensen K, Patel A, Klubo-Gwiezdzinska J, Bauer A, Vasko V.

Endocr Relat Cancer. 2011 Sep 20;18(5):613-26. doi: 10.1530/ERC-10-0289. Print 2011 Oct.

PMID:
21813730
34.

Clinical review: Ectopic cervical thyroid carcinoma--review of the literature with illustrative case series.

Klubo-Gwiezdzinska J, Manes RP, Chia SH, Burman KD, Stathatos NA, Deeb ZE, Wartofsky L.

J Clin Endocrinol Metab. 2011 Sep;96(9):2684-91. doi: 10.1210/jc.2011-0611. Epub 2011 Jul 13. Review.

PMID:
21752893
35.

Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?

Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L.

Clin Endocrinol (Oxf). 2011 Jan;74(1):111-7. doi: 10.1111/j.1365-2265.2010.03898.x.

PMID:
21054476
36.

Salivary gland malignancy and radioiodine therapy for thyroid cancer.

Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD, Vasko V, Chia S, Deng T, Kulkarni K, Wartofsky L.

Thyroid. 2010 Jun;20(6):647-51. doi: 10.1089/thy.2009.0466.

PMID:
20470209
37.

Metastases of well-differentiated thyroid cancer to the gastrointestinal system.

Klubo-Gwiezdzinska J, Morowitz D, Van Nostrand D, Burman KD, Vasko V, Soberman M, Wartofsky L.

Thyroid. 2010 Apr;20(4):381-7. doi: 10.1089/thy.2009.0280. Review.

PMID:
20210670
38.

Serum endostatin levels in patients with metastatic and non-metastatic well-differentiated thyroid cancer.

Kłubo-Gwieździńska J, Junik R, Kopczyńska E.

Endokrynol Pol. 2010 Jan-Feb;61(1):7-12.

39.

Thyrotropin blood levels, subclinical hypothyroidism, and the elderly patient.

Klubo-Gwiezdzinska J, Wartofsky L.

Arch Intern Med. 2009 Nov 23;169(21):1949-51. doi: 10.1001/archinternmed.2009.415. No abstract available.

PMID:
19933954
40.

[The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Kłubo-Gwieździńska J, Junik R.

Endokrynol Pol. 2008 Mar-Apr;59(2):123-30. Polish.

41.
42.

Papillary thyroid cancer with metastasis to the skin.

Junik R, Kłubo-Gwieździńska J, Zuchora Z, Zmyslowski W.

Clin Nucl Med. 2006 Jul;31(7):435-6. No abstract available.

PMID:
16785820
43.

[Endocrine disorders as a result of alcohol abuse].

Junik R, Kłubo-Gwiezdzińska J.

Pol Arch Med Wewn. 2004 May;111(5):603-8. Review. Polish. No abstract available.

PMID:
15508813

Supplemental Content

Loading ...
Support Center